Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Stifel CNS Day Transcript

Apr 01, 2021 / 03:00PM GMT
Release Date Price: $141.81 (+0.44%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much. It's my pleasure to be on a panel with Akshay for -- I don't know how many of these we've done together, Akshay, but it's always fun. So thank you so much for attending. And for those listening, this is always, I think, a unique experience to talk more about what Alnylam is doing in neurology as that often gets overlooked, but it's now progressing pretty quickly towards going into patients.

So with that, Akshay, I just want to thank you again.

Questions & Answers

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

And maybe just to start, could you sort of set the stage on your efforts in neuro and the status of your first couple of candidates?

Akshay K. Vaishnaw
Alnylam Pharmaceuticals, Inc. - President of Research & Development

Yes. Let's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot